Recent coverage has highlighted that Orthocell’s flagship nerve repair product, Remplir™, is expected to be exempt from newly proposed US tariffs targeting pharmaceutical imports.

Read more

The AFR has profiled Orthocell’s increased investment in Marine Biomedical and its novel bone-repair technology, PearlBone™, in this article by Tom Rabe titled ‘The company repairing human bone with Kimberley pearl shells.’ 

Orthocell Chairman John Van Der Wielen explains that this investment contributes to Orthocell’s broader strategy to support surgeons with a more complete trauma-repair toolkit spanning nerve, tendon and bone, while bringing new Australian-made biomedical innovation to international markets. 

Here’s an excerpt: 

“It’s the same market in a sense, and all of the surgeons dealing with trauma will tell you that when you’ve got a gunshot injury or a major trauma from a car accident, you need bone, nerve and tendon,” Van Der Wielen said. 

With regulatory approvals already secured for Orthocell’s nerve repair device, Remplir™, across Australia, the US, Canada, Singapore and Hong Kong, and PearlBone now progressing toward US approval, Orthocell is executing a long-term strategy to expand across multiple surgical indications and markets. 

Read the article.